Alnylam Pharmaceuticals Inc RNAi Roundtable Webcast Transcript
Good morning, everyone. I'm Chris Brickley, Director of Investor Relations at Alnylam, I'm pleased to be kicking off our 10th RNAi Roundtable series this morning. Throughout these events, we aim to highlight a few of the exciting programs in our pipeline that represent some of the next wave of transformative medicines we expect to deliver from our RNAi platform.
Today, we'll be covering ALN-6400, which is an investigational therapy targeting plasminogen with the potential to address rare bleeding disorders. Today's event is expected to run approximately 75 minutes.
Pushkal will moderate a question-and-answer session at the conclusion of the presentations. If you'd like to submit a question, you can do so at any time during the event by typing your question in the Ask a Question field located within the webcast platform.
As a reminder, we will be making forward-looking statements during this webinar, we encourage you to read our most recent SEC filings for a more complete
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
